D
Cytokinetics, Incorporated
CYTK
$43.27
-$0.61-1.39%
D
Sell
12/26/2024Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D- from E+ on 12/26/2024 due to an increase in the volatility index and valuation index.
Cytokinetics, Incorporated (CYTK) was upgraded to D- from E+ on 12/26/2024 due to an increase in the volatility index and valuation index.
E
Sell
12/2/2024Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to E+ from D- on 12/2/2024 due to a decline in the volatility index and total return index.
Cytokinetics, Incorporated (CYTK) was downgraded to E+ from D- on 12/2/2024 due to a decline in the volatility index and total return index.
D
Sell
11/11/2024Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D- from E+ on 11/11/2024 due to an increase in the valuation index.
Cytokinetics, Incorporated (CYTK) was upgraded to D- from E+ on 11/11/2024 due to an increase in the valuation index.
E
Sell
10/21/2024Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to E+ from D- on 10/21/2024 due to a decline in the valuation index, total return index and volatility index.
Cytokinetics, Incorporated (CYTK) was downgraded to E+ from D- on 10/21/2024 due to a decline in the valuation index, total return index and volatility index.
D
Sell
3/14/2023Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D+ on 03/14/2023.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D+ on 03/14/2023.
D
Sell
2/9/2023Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 02/09/2023.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 02/09/2023.
D
Sell
2/8/2023Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D+ on 2/8/2023 due to a large decline in the total return index, volatility index and valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D+ on 2/8/2023 due to a large decline in the total return index, volatility index and valuation index.
D
Sell
11/7/2022Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 11/7/2022 due to an increase in the valuation index, volatility index and growth index. Operating cash flow increased 7.11% from -$90.48M to -$84.04M.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 11/7/2022 due to an increase in the valuation index, volatility index and growth index. Operating cash flow increased 7.11% from -$90.48M to -$84.04M.
D
Sell
5/31/2022Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 5/31/2022 due to a significant increase in the total return index.
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 5/31/2022 due to a significant increase in the total return index.
D
Sell
5/13/2022Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and valuation index. EBIT declined 258.72% from -$21.7M to -$77.86M, earnings per share declined from -$0.3636 to -$1.0523, and debt to equity increased from 0.65 to 1.81.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the growth index, solvency index and valuation index. EBIT declined 258.72% from -$21.7M to -$77.86M, earnings per share declined from -$0.3636 to -$1.0523, and debt to equity increased from 0.65 to 1.81.
D
Sell
5/5/2022Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 5/5/2022 due to an increase in the total return index and valuation index.
D
Sell
4/20/2022Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index, volatility index and valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 4/20/2022 due to a significant decline in the total return index, volatility index and valuation index.
D
Sell
12/13/2021Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 12/13/2021 due to a decline in the total return index and volatility index.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 12/13/2021 due to a decline in the total return index and volatility index.
D
Sell
11/19/2021Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 11/19/2021 due to an increase in the volatility index and total return index.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 11/19/2021 due to an increase in the volatility index and total return index.
D
Sell
11/8/2021Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 11/8/2021 due to a decline in the valuation index.
D
Sell
10/9/2020Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 10/9/2020 due to a decline in the total return index and valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 10/9/2020 due to a decline in the total return index and valuation index.
D
Sell
5/20/2020Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 5/20/2020 due to an increase in the total return index, growth index and volatility index.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 5/20/2020 due to an increase in the total return index, growth index and volatility index.
D
Sell
4/6/2020Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 4/6/2020 due to an increase in the volatility index and valuation index.
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 4/6/2020 due to an increase in the volatility index and valuation index.
D
Sell
3/9/2020Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 3/9/2020 due to a large decline in the growth index, volatility index and efficiency index. Total revenue declined 13.92% from $6.06M to $5.21M, net income declined 3.61% from -$29.57M to -$30.64M, and earnings per share declined from -$0.5043 to -$0.5182.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 3/9/2020 due to a large decline in the growth index, volatility index and efficiency index. Total revenue declined 13.92% from $6.06M to $5.21M, net income declined 3.61% from -$29.57M to -$30.64M, and earnings per share declined from -$0.5043 to -$0.5182.
D
Sell
8/13/2019Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 8/13/2019 due to a large increase in the growth index, total return index and volatility index. Operating cash flow increased 8.29% from -$26.91M to -$24.68M.
Cytokinetics, Incorporated (CYTK) was upgraded to D from D- on 8/13/2019 due to a large increase in the growth index, total return index and volatility index. Operating cash flow increased 8.29% from -$26.91M to -$24.68M.
D
Sell
3/12/2018Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 3/12/2018 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 100.29% from $6.18M to -$18, EBIT declined 28.51% from -$28.42M to -$36.53M, and earnings per share declined from -$0.6023 to -$0.7569.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 3/12/2018 due to a large decline in the total return index, volatility index and growth index. Total revenue declined 100.29% from $6.18M to -$18, EBIT declined 28.51% from -$28.42M to -$36.53M, and earnings per share declined from -$0.6023 to -$0.7569.
D
Sell
11/6/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 11/6/2017 due to a large decline in the total return index, growth index and efficiency index. Total capital declined 13.56% from $205.16M to $177.34M, EBIT declined 12.82% from -$25.19M to -$28.42M, and net income declined 11.27% from -$29.08M to -$32.36M.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 11/6/2017 due to a large decline in the total return index, growth index and efficiency index. Total capital declined 13.56% from $205.16M to $177.34M, EBIT declined 12.82% from -$25.19M to -$28.42M, and net income declined 11.27% from -$29.08M to -$32.36M.
D
Sell
10/25/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 10/25/2017 due to a decline in the total return index.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 10/25/2017 due to a decline in the total return index.
C
Hold
10/9/2017Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 10/9/2017 due to a large increase in the total return index.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 10/9/2017 due to a large increase in the total return index.
D
Sell
9/22/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 9/22/2017 due to a large decline in the total return index and valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 9/22/2017 due to a large decline in the total return index and valuation index.
C
Hold
9/7/2017Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 9/7/2017 due to an increase in the total return index.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 9/7/2017 due to an increase in the total return index.
D
Sell
8/10/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 8/10/2017 due to a large decline in the total return index and efficiency index. Net income declined 12.43% from -$25.87M to -$29.08M.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 8/10/2017 due to a large decline in the total return index and efficiency index. Net income declined 12.43% from -$25.87M to -$29.08M.
C
Hold
7/21/2017Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 7/21/2017 due to an increase in the total return index and volatility index.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 7/21/2017 due to an increase in the total return index and volatility index.
D
Sell
6/29/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 6/29/2017 due to a decline in the total return index and solvency index.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 6/29/2017 due to a decline in the total return index and solvency index.
C
Hold
5/10/2017Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to C- from C on 5/10/2017 due to a substantial decline in the valuation index, efficiency index and solvency index. Net income declined 461.42% from $7.16M to -$25.87M.
Cytokinetics, Incorporated (CYTK) was downgraded to C- from C on 5/10/2017 due to a substantial decline in the valuation index, efficiency index and solvency index. Net income declined 461.42% from $7.16M to -$25.87M.
C
Hold
3/8/2017Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C from C- on 3/8/2017 due to a substantial increase in the valuation index, efficiency index and total return index. Total capital increased 8.54% from $114.47M to $124.24M.
Cytokinetics, Incorporated (CYTK) was upgraded to C from C- on 3/8/2017 due to a substantial increase in the valuation index, efficiency index and total return index. Total capital increased 8.54% from $114.47M to $124.24M.
C
Hold
12/27/2016Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 12/27/2016 due to a noticeable increase in the total return index, solvency index and efficiency index.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 12/27/2016 due to a noticeable increase in the total return index, solvency index and efficiency index.
D
Sell
12/1/2016Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 12/1/2016 due to a noticeable decline in the total return index and valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 12/1/2016 due to a noticeable decline in the total return index and valuation index.
C
Hold
11/15/2016Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 11/15/2016 due to a noticeable increase in the total return index and solvency index.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D+ on 11/15/2016 due to a noticeable increase in the total return index and solvency index.
D
Sell
11/4/2016Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 11/4/2016 due to a substantial increase in the growth index, efficiency index and solvency index. Total revenue increased 917.7% from $5.8M to $59.05M, net income increased 374.63% from -$11.61M to $31.89M, and earnings per share increased from -$0.2927 to $0.74.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D- on 11/4/2016 due to a substantial increase in the growth index, efficiency index and solvency index. Total revenue increased 917.7% from $5.8M to $59.05M, net income increased 374.63% from -$11.61M to $31.89M, and earnings per share increased from -$0.2927 to $0.74.
D
Sell
8/5/2016Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 8/5/2016 due to a significant decline in the growth index, volatility index and solvency index. Total revenue declined 31.1% from $8.42M to $5.8M, debt to equity increased from 0.51 to 0.61, and the quick ratio declined from 4.19 to 3.44.
Cytokinetics, Incorporated (CYTK) was downgraded to D- from D on 8/5/2016 due to a significant decline in the growth index, volatility index and solvency index. Total revenue declined 31.1% from $8.42M to $5.8M, debt to equity increased from 0.51 to 0.61, and the quick ratio declined from 4.19 to 3.44.
D
Sell
10/20/2015Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 10/20/2015 due to a substantial decline in the volatility index and total return index.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 10/20/2015 due to a substantial decline in the volatility index and total return index.
D
Sell
10/1/2015Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 10/1/2015 due to an increase in the total return index and valuation index.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 10/1/2015 due to an increase in the total return index and valuation index.
D
Sell
9/16/2015Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 9/16/2015 due to a decline in the valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 9/16/2015 due to a decline in the valuation index.
D
Sell
8/7/2015Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 8/7/2015 due to a decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 4.29 to 3.61, and total capital declined 11.04% from $84.15M to $74.86M.
Cytokinetics, Incorporated (CYTK) was downgraded to D+ from C- on 8/7/2015 due to a decline in the volatility index, solvency index and efficiency index. The quick ratio declined from 4.29 to 3.61, and total capital declined 11.04% from $84.15M to $74.86M.
C
Hold
3/6/2015Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D on 3/6/2015 due to an increase in the volatility index, efficiency index and solvency index. Total capital increased 25.04% from $73.63M to $92.06M.
Cytokinetics, Incorporated (CYTK) was upgraded to C- from D on 3/6/2015 due to an increase in the volatility index, efficiency index and solvency index. Total capital increased 25.04% from $73.63M to $92.06M.
D
Sell
2/27/2015Downgrade
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 2/27/2015 due to a decline in the valuation index.
Cytokinetics, Incorporated (CYTK) was downgraded to D from D+ on 2/27/2015 due to a decline in the valuation index.
D
Sell
2/12/2015Upgraded
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 2/12/2015 due to a significant increase in the growth index, volatility index and efficiency index. Total revenue increased 20.89% from $7.79M to $9.42M, and operating cash flow increased 1.48% from -$9.38M to -$9.52M.
Cytokinetics, Incorporated (CYTK) was upgraded to D+ from D on 2/12/2015 due to a significant increase in the growth index, volatility index and efficiency index. Total revenue increased 20.89% from $7.79M to $9.42M, and operating cash flow increased 1.48% from -$9.38M to -$9.52M.
NASDAQ
03/06/2025 4:00PM Eastern
Quotes delayed
